Histogenics Corporation to Host Investor Day on June 19, 2018
31 mai 2018 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored...
Histogenics Corporation Announces First Quarter 2018 Financial and Operating Results
10 mai 2018 06h30 HE
|
Histogenics Corporation
‒ Top-line Superiority Data from NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Submission on Track for Third Quarter of 2018 ‒‒ Initiation of Phase 3 Clinical Trial in...
Histogenics Corporation to Present at Upcoming Investor Conferences
28 mars 2018 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Corporation Announces Financial and Operating Results for the Fourth Quarter and Year Ended December 31, 2017
15 mars 2018 06h00 HE
|
Histogenics Corporation
NeoCart® Top-line Phase 3 Clinical Trial Data and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 NeoCart Licensing Agreement with MEDINET Co. Ltd. Provides...
Histogenics to Showcase NeoCart® at American Academy of Orthopedic Surgeons and Orthopedic Research Society 2018 Annual Meetings
02 mars 2018 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Corporation to Present at Upcoming Investor Conferences
20 févr. 2018 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain...
Histogenics Corporation Announces Closing of Underwritten Registered Direct Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
25 janv. 2018 16h05 HE
|
Histogenics Corporation
WALTHAM, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leader in the development of restorative cell therapies, today announced the closing of its...
Histogenics Corporation and MEDINET Co., Ltd Enter Into Licensing Agreement for Development and Commercialization of NeoCart for the Japanese Market
21 déc. 2017 06h00 HE
|
Histogenics Corporation
– Transaction Terms Include a $10 Million Up-front Payment with a Potential of $87 Million in Total Milestones, and Tiered Royalties on Sales ‒ ‒ Japanese Cartilage Repair Market is Large and Growing...
Histogenics Corporation Announces Third Quarter 2017 Financial and Operating Results
09 nov. 2017 06h30 HE
|
Histogenics Corporation
Top-line, 1-year Superiority Data for NeoCart® Phase 3 Clinical Trial and Potential Biologics License Application Filing Remain on Track for Third Quarter of 2018 Company to Host Conference Call...
Histogenics Corporation Promotes Stephen Kennedy to Executive Vice President & Chief Operating Officer
12 oct. 2017 09h00 HE
|
Histogenics Corporation
WALTHAM, Mass., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a leading cell therapy company focused on developing and commercializing products in the...